Table of Contents
ISRN Endocrinology
Volume 2012 (2012), Article ID 798146, 11 pages
http://dx.doi.org/10.5402/2012/798146
Research Article

Efficacy of Various Antidiabetic Agents as Add-On Treatments to Metformin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis

1Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon-Pathom 73000, Thailand
2Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand

Received 11 November 2011; Accepted 6 December 2011

Academic Editors: M. Krebs and O. Torffvit

Copyright © 2012 Nalinee Poolsup et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation, “Facts & figures: prevalence 2007,” August 2009, http://www.idf.org/home/index.cfm?node=264.
  2. O. Pinhas-Hamiel and P. Zeitler, “Acute and chronic complications of type 2 diabetes mellitus in children and adolescents,” Lancet, vol. 369, no. 9575, pp. 1823–1831, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. I. M. Stratton, A. I. Adler, H. A. W. Neil et al., “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” British Medical Journal, vol. 321, no. 7258, pp. 405–412, 2000. View at Google Scholar · View at Scopus
  4. B. K. Tripathi and A. K. Srivastava, “Diabetes mellitus: complications and therapeutics,” Medical Science Monitor, vol. 12, no. 7, pp. RA130–RA147, 2006. View at Google Scholar · View at Scopus
  5. R. Turner, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar
  6. R. Turner, “Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34),” Lancet, vol. 352, no. 9131, pp. 854–865, 1998. View at Publisher · View at Google Scholar
  7. International Diabetes Federation, “Global guideline for type 2 diabetes,” August 2009, http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf.
  8. H. W. Rodbard, L. Blonde, S. S. Braithwaite et al., “American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus,” Endocrine Practice, vol. 13, no. 1, pp. 1–68, 2007. View at Google Scholar · View at Scopus
  9. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy,” Diabetes Care, vol. 32, no. 1, pp. 193–203, 2009. View at Publisher · View at Google Scholar · View at PubMed
  10. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: aonsensus statement from the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetologia, vol. 52, no. 1, pp. 17–30, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. National Institute for Health and Clinical Excellence, “NICE clinical guideline 87-type 2 diabetes: the management of type 2 diabetes,” August 2009, http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf.
  12. R. S. Hundal and S. E. Inzucchi, “Metformin: New understandings, new uses,” Drugs, vol. 63, no. 18, pp. 1879–1894, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. R. C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49),” Journal of the American Medical Association, vol. 281, no. 21, pp. 2005–2012, 1999. View at Publisher · View at Google Scholar
  14. K. K. Ray, S. R. K. Seshasai, S. Wijesuriya et al., “Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials,” The Lancet, vol. 373, no. 9677, pp. 1765–1772, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. NHS Clinical Governance Support Team, “National Diabetes Support Team Factsheet No 15,” January 2006, http://www.diabetes.nhs.uk/document.php?o=134.
  16. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: Is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. J. J. Deeks, J. P. T. Higgins, and D. G. Altman, “Analysing and presenting results,” in Cochrane Handbook for Systematic Reviews of Interventions 426, J. P. T. Higgins and S. Green, Eds., pp. 120–122, Jonh Wiley & Sons, Chichester, UK, 2006. View at Google Scholar
  18. A. Whitehead and J. Whitehead, “A general parametric approach to the meta-analysis of randomized clinical trials,” Statistics in Medicine, vol. 10, no. 11, pp. 1665–1677, 1991. View at Google Scholar · View at Scopus
  19. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Google Scholar · View at Scopus
  20. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Google Scholar · View at Scopus
  21. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Google Scholar · View at Scopus
  22. R. Scott, T. Loeys, M. J. Davies, and S. S. Engel, “Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 10, no. 10, pp. 959–969, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. G. Bolli, F. Dotta, L. Colin, B. Minic, and M. Goodman, “Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin,” Diabetes, Obesity and Metabolism, vol. 11, no. 6, pp. 589–595, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. B. Charbonnel, G. Schernthaner, P. Brunetti et al., “Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes,” Diabetologia, vol. 48, no. 6, pp. 1093–1104, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. A. Garber, E. Klein, S. Bruce, S. Sankoh, and P. Mohideen, “Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy,” Diabetes, Obesity and Metabolism, vol. 8, no. 2, pp. 156–163, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. G. Umpierrez, M. Issa, and A. Vlajnic, “Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial,” Current Medical Research and Opinion, vol. 22, no. 4, pp. 751–759, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. A. Hamann, J. Garcia-Puig, G. Paul, J. Donaldson, and M. Stewart, “Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 1, pp. 6–13, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. G. Derosa, A. D'Angelo, P. D. Ragonesi et al., “Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome,” Journal of Clinical Pharmacy and Therapeutics, vol. 31, no. 4, pp. 375–383, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. Kvapil, A. Swatko, C. Hilberg, and M. Shestakova, “Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 8, no. 1, pp. 39–48, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. J. E. B. Reusch and B. B. Draznin, “Atherosclerosis in diabetes and insulin resistance,” Diabetes, Obesity and Metabolism, vol. 9, no. 4, pp. 455–463, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Diamant and R. J. Heine, “Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence,” Drugs, vol. 63, no. 13, pp. 1373–1405, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Rendell, “The role of sulphonylureas in the management of type 2 diabetes mellitus,” Drugs, vol. 64, no. 12, pp. 1339–1358, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci, “Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis,” Diabetes Research and Clinical Practice, vol. 79, no. 2, pp. 196–203, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus